Skip to main content

Table 1 Clinical features, immunophenotype of patients with the t(9;11)(p22p15).

From: Fusion of the NUP98 gene with the LEDGF/p52 gene defines a recurrent acute myeloid leukemia translocation

Patient

Sex/Age

WCC × 109/L

Diagnosis

Survival (months)

Immunophenotype (where less than 50% of cells are involved, the fraction is given).

Reference

1

F/20

63.8

AML M1

3

CD33 (50%), CD13 (10%) negative for CD11b, CD 14 HLA DR, CD34 CD 19, CD22, negative for CD 10 negative for CD2, CD5, CD7, CD41, CD61, CD62 Nuclear TdTnegative. Blasts were positive for PAS, Sudan black and myeloperoxidase and negative for non-specific esterase.

1

2

M/52

50.5

AML M1

9

CD33, CD13, CD11c, CD15 (15%), CD36 HLA-DR, negative for CD34 negative for CD10, CD19, CD20, CD56 CD4 (20%), negative for CD5, CD7 Blasts were positive for myeloperoxidase with a subset positive for non-specific esterase.

2

3

F/60

1.5

AML M2

54

CD33, CD13, CD11b (14%) negative for CD34, HLA-DR negative for CD10, CD19, CD20 negative for CD2, CD3, CD5

This report

  1. Details of the three patients discussed in this study are presented. All features except for survival are at presentation. Where surface markers are positive in less than 50% of cells, the proportion of positive cells is indicated in parentheses.